Last updated: May 3, 2026
What does CA2686267 protect, and what is its claim scope?
CA2686267 is a Canadian patent publication number tied to a defined pharmaceutical subject matter, with enforceable scope determined by the claims (independent claim language) and constrained by the description and prosecution history. The actionable claim scope for Canadian enforcement is the set of product, composition, and method claims actually granted for the Canadian family member, plus any dependent claims that narrow those independent claims.
This analysis requires the exact claim set (verbatim claim text) from the Canadian publication record (CA2686267) and, for a complete landscape, the legal status (granted/withdrawn/terminated), claim amendment history, and the specific Canadian family identifiers (priority and related WO/EP/US applications). Those elements are not provided in the prompt, and the analysis cannot be produced without the claim text and legal status.
What are the independent claims and how do dependent claims narrow protection?
A complete scope analysis requires:
- The verbatim independent claim(s) (typically composition-of-matter, pharmaceutical composition, and/or method-of-treatment).
- The verbatim dependent claims that define narrower embodiments (e.g., specific salts, polymorphs, formulation components, dosage regimens, patient populations, biomarker-defined cohorts, combination therapies).
- Whether claims are drafted as “comprising” vs “consisting of,” and whether product claims include functional language that can broaden or narrow infringement theories.
Without the claim text, any “scope” description would be non-actionable and potentially inaccurate.
How does CA2686267 fit into the Canadian patent landscape?
A landscape analysis for CA2686267 must map:
- Family members (WO, EP, US, and any regional national filings) and whether Canadian claims track those jurisdictions.
- Competing Canadian patents covering:
- The same active ingredient (same chemical entity).
- Alternative salts/polymorphs and formulation approaches.
- Combination regimens that share the same backbone.
- Method-of-treatment claims that target the same therapeutic use.
- Regulatory linkage:
- Patent listing and associated product monographs in Canada.
- Patent expiry dates (including term adjustments if applicable).
- Patent term extension (where available) and whether the listing is triggered by FDA/EMA timelines or Canadian regulatory milestones.
None of those required inputs can be derived from the provided prompt.
What is the enforceable status of CA2686267 in Canada?
To determine enforceable protection in Canada, the analysis must include:
- Current legal status (granted vs active vs expired vs lapsed).
- Any re-examination or reissue, and any claim amendments.
- Whether the patent is subject to impeachment (e.g., invalidity challenges) or enforcement stays.
- Whether the patent is listed under the Patented Medicines (Notice of Compliance) regime and whether it is associated with a specific DIN/NOC record.
The prompt provides no legal status information.
What are the likely infringement “entry points” in Canada for CA2686267?
For a pharmaceutical patent in Canada, infringement entry points typically cluster into:
- Sale/import/manufacture of claimed compositions or products.
- Use of the claimed method-of-treatment for a claimed patient group under a claimed regimen.
- Direct or inducement theories tied to instructions on labeling, physician use, and commercial distribution.
But identifying the actual entry points requires the exact claim language.
Actionable landscape framework (what the landscape would include once claims are extracted)
The framework below shows the structure of a complete, business-useful landscape for CA2686267. It cannot be populated with CA-specific facts without the CA2686267 record and claim text.
| Landscape layer |
What to extract from CA2686267 |
What to compare across Canada |
Business use |
| Claim architecture |
Independent claim type(s): composition, method, use, combination; claim construction levers (salt/form, range language, “comprising,” dosage) |
Overlap with competing patents on same chemical entity and same therapeutic use |
Design-around targets and freedom-to-operate |
| Formulation scope |
Excipients, delivery system (if claimed), particle size/polymorph (if claimed) |
Competing formulation patents for same drug substance |
Product strategy and formulation IP positioning |
| Combination scope |
Which co-therapies are claimed; sequence and timing if stated |
Other combination regimens filed in Canada |
Partnering and launch sequencing |
| Regulatory linkage |
NOC listing, claims that map to the listed patent summary |
Which other patents are “stacked” against same product |
Litigation risk and challenge likelihood |
| Expiry & term |
Expiry dates, patent term adjustment/extension (if applicable), patent protection endgame |
How quickly competitors can enter based on earliest expiring claim sets |
Investment timing and go/no-go milestones |
Key Takeaways
- A correct scope-and-claims analysis for Canada patent CA2686267 requires the verbatim claim text and current legal status from the Canadian patent record.
- A valid patent landscape needs family mapping (priority and related WO/EP/US), Canada legal status, and Canadian regulatory linkage (NOC listing if present).
- The prompt does not contain these essential facts, so a complete, accurate, and actionable analysis cannot be produced.
FAQs
-
What determines infringement scope in Canada for a pharmaceutical patent?
The scope is defined by the patent’s granted claims, interpreted in context with the description and file history.
-
Why does claim wording matter (e.g., “comprising” vs “consisting of”)?
“Comprising” typically allows additional elements, which can broaden coverage relative to more restrictive “consisting of” language.
-
How does a Canadian NOC listing affect the practical value of a patent?
It determines which patent is triggered in the Patented Medicines (Notice of Compliance) regime and therefore shapes litigation and market-entry timing.
-
What is the fastest way competitors usually design around a pharma patent?
By changing non-essential claim parameters (salt/formulation/dose regimen/co-therapy) that do not fall within narrowed dependent claim embodiments.
-
How do family members influence Canadian claim scope?
They provide drafting patterns and claim evolution across jurisdictions, but Canadian claims can diverge due to amendments and prosecution outcomes.
References
[1] Canadian Intellectual Property Office (CIPO). Patent database entry for CA2686267 (publication and legal status).
[2] Patented Medicines (Notice of Compliance) Regulations, Canada.
[3] Patent Act, R.S.C., 1985, c. P-4 (Canada).
